Effects of single doses of two antihypertensive rauwolfia-diuretic combinations on urinary excretion.
In a double-blind placebo-controlled investigation, 14 healthy adult male volunteers were studied to assess and compare the urinary effects of acute single doses of two antihypertensive formulations containing: hydroflumethiazide 50 mg, Rauwolfia serpentina 50 mg and potassium chloride 625 mg (HFRK) (Rautrax-50; Squibb Laboratories); and clopamide 5 mg, reserpine 0.1 mg and dihydroergocristine 0.5 mg (CRE) (Brinerdin; Sandoz Products). Both significantly increased mean 24-hour urinary outputs of fluid, Cl-, Na+, K+ and Mg2+. CRE increased creatinine and decreased Ca2+ output. After dosing, times to maximal urinary flow of fluid, Cl-, Na+, Ca2+ and creatinine were shortened by HFRK and CRE and those corresponding to K+, Mg2+, phosphate and urate were unaffected. Both formulations thus acted mainly through their diuretic constituents.
D000293:Adolescent; D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology*; D003005:Clopamide / Q000494:pharmacology; D004088:Dihydroergotoxine / Q000494:pharmacology; D004232:Diuretics / Q000494:pharmacology*; D004311:Double-Blind Method; D004338:Drug Combinations; D004573:Electrolytes / Q000097:blood / Q000652:urine*; D006801:Humans; D006857:Hydroflumethiazide / Q000494:pharmacology; D008297:Male; D011189:Potassium Chloride / Q000494:pharmacology; D011897:Random Allocation; D012110:Reserpine / Q000494:pharmacology; D046948:Secologanin Tryptamine Alkaloids / Q000494:pharmacology*; D013997:Time Factors; D014554:Urination / Q000187:drug effects*
D000959:Antihypertensive Agents; D004232:Diuretics; D004338:Drug Combinations; D004573:Electrolytes; D046948:Secologanin Tryptamine Alkaloids; D004088:Dihydroergotoxine; D003005:Clopamide; D006857:Hydroflumethiazide; D011189:Potassium Chloride; D012110:Reserpine